Researchers at the Ångström Laboratory in Uppsala, Sweden have discovered a new method to manufacture nanomaterial sensors so that it becomes possible to for example measure different components of body liquids, i.e. blood or amniotic fluid.

Nanexa AB, the company that now owns this technology, has recently signed an exclusive agreement with Neoventa Medical AB to develop this very promising technology with in the perinatal care area. In the first application Neoventa and Nanexa will develop a sensor that measures lactate during labour and delivery. Lactate is an indicator for oxygen depletion of the fetus.

Read the full press release here (PDF)

Researchers at the Ångström Laboratory in Uppsala, Sweden have discovered a new method to manufacture nanomaterial sensors so that it becomes possible to for example measure different components of body liquids, i.e. blood or amniotic fluid.

Nanexa AB, the company that now owns this technology, has recently signed an exclusive agreement with Neoventa Medical AB to develop this very promising technology with in the perinatal care area. In the first application Neoventa and Nanexa will develop a sensor that measures lactate during labour and delivery. Lactate is an indicator for oxygen depletion of the fetus.

Read the full press release here (PDF)

The complete article is now available FREE of charge on the Obstetrics & Gynecology webpage here.

STAN Viewer Live is the latest addition to Neoventa’s tools for an efficient and safe workflow, offering a user friendly solution for remote viewing of ongoing STAN recordings. STAN Viewer Live is the only product for remote viewing of STAN recordings that, apart from the actual recording, also shows the fetal ECG average forming the basis for the ST Analysis. For mor information, please see the STAN Viewer Live product page here.

For more information, please read the full press release in PDF-format here.

For more information, please read the full press release in PDF-format here.

Updated: Read the full article "Reduced prevalence of metabolic acidosis at birth:..." for free (ePrint)

The study included 5 681 high risk patients, randomly assigned to either monitoring by CTG or CTG+ST Analysis. The primary outcome of the study was metabolic acidosis, defined as pH < 7.05 and Base Deficit in extracellular fluid (BDecf) > 12mmol/l. The result also includes metabolic acidosis calculated in blood (BDblood). Other secondary outcomes were operative deliveries, Apgar scores, admissions to NICU and number of FBS.

There was a 30% reduction of metabolic acidosis in the CTG+ST Analysis group. When base deficit was calculated in blood there was a significant reduction in metabolic acidosis with 44 %. At the same time, there was a 48% reduction in the use of FBS in the CTG+ST arm. These effects were achieved without any increase in operative deliveries. There were no effects on other neonatal outcomes. These results are consistent with the results of the meta-analysis of earlier randomised trials published in the Cochrane report.

The Dutch RCT was powered on the assumption that 3.5% of newborn would have metabolic acidosis at birth. In reality, the rate was much lower (1.1% in the CTG arm and 0.7% in the CTG+ST Analysis arm), explaining why the 30% reduction in primary outcome, although substantial, did not reach statistical significance. The 44% reduction in the metabolic acidosis in blood was however significant.

There is no consensus which method to use for calculating base deficit and metabolic acidosis: in the intracellular fluid or in blood. Researchers mostly use the first method, while in clinical practice the second is most common (since it is automatically calculated by most blood gas analysers). Both methods showed a substantial reduction of metabolic acidosis in the CTG+ST arm.

The Dutch RCT is one of the largest trials ever within obstetrics. It was performed in nine centres: three academic hospitals and six non-academic teaching hospitals. Most hospitals in the study did not have any previous experience of STAN. The study was performed without any involvement from Neoventa.